Literature DB >> 2240355

Further phenotypic evidence that nodular, lymphocyte-predominant Hodgkin's disease is a large B-cell lymphoma in evolution.

S M Chittal1, C Alard, J F Rossi, T al Saati, A Le Tourneau, J Diebold, G Delsol.   

Abstract

Five cases of nodular, lymphocyte predominant Hodgkin's disease (nLP HD), in which an association with (n = 3) and transformation to (n = 2) large cell lymphoma (LCL) were found, were studied with monoclonal antibodies against B-, T-, and Reed-Sternberg (R-S) cell-associated antigens and epithelial membrane antigen (EMA) on paraffin sections. Both lymphocytic (L) and histiocytic (H) cells of nLP HD and lymphoma cells of LCL expressed multiple B-cell-associated antigens (detected by LN-1/CDw75, L26, MB2, DBB.42, DBA.44, DND.53, DNA.7 antibodies) but did not react with antibodies against T-cell-associated (MT1, UCHL1/CD45RO) (one exception for CD45RO in LCL) and R-S cell-associated (Leu-M1/CD15, Ber-H2/CD30) antigens. EMA was expressed by L and H cells in all cases and conserved in LCL cells, emphasizing the frequent expression of EMA by the diagnostic cells of nLP HD. An antibody (BNH9) against blood group-related antigens (H and Y oligosaccharide antigens) that does not normally react with lymphoid cells was found to be reactive with few L and H cells in two of five and most LCL cells in four of five cases. The finding might be indicative of abnormal activation of lymphoid cells. The data reinforce current implications that nLP HD is a B-cell malignancy in evolution and that it is not truly representative of Hodgkin's disease in terms of biological and clinical behavior.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240355     DOI: 10.1097/00000478-199011000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.

Authors:  A Miyata; K Kojima; T Yoshino; S Fujii; K Shinagawa; K Ichimura
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction.

Authors:  C Schmid; C Sargent; P G Isaacson
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

3.  Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.

Authors:  Joo Y Song; Franziska C Eberle; Liqiang Xi; Mark Raffeld; Osama Rahma; Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

4.  Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen.

Authors:  G Delsol; F Meggetto; P Brousset; E Cohen-Knafo; T al Saati; P Rochaix; B Gorguet; B Rubin; J J Voigt; S Chittal
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

5.  Lymphocyte predominance Hodgkin's disease. Evidence for a kappa light chain-restricted monotypic B-cell neoplasm.

Authors:  M H Stoler; G E Nichols; M Symbula; L M Weiss
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

6.  Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease.

Authors:  G Delsol; P Brousset; S Chittal; F Rigal-Huguet
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

7.  Leu 7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin's disease from nodular sclerosing Hodgkin's disease, T-cell-rich B-cell lymphoma and follicular lymphoma.

Authors:  O W Kamel; A B Gelb; R B Shibuya; R A Warnke
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

8.  Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30+) lymphomas.

Authors:  G Delsol; A Blancher; T al Saati; E Ralfkiaer; A Lauritzen; L Bruigères; P Brousset; F Rigal-Huguet; C Mazerolles; A Robert
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.